BioSpace News Archive

Business

Amryt Reports Q3 2022 Financial and Operational Results

Amryt provides a business update and announces unaudited financial results for the third quarter ended September30, 2022.

November 3, 2022
·
84 min read
Pharm Country

TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum

TELA Bio, Inc. announced that the Company will participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on November 17th, 2022.

November 3, 2022
·
1 min read
Business

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Keros Therapeutics, Inc. provided a business update and reported financial results for the quarter ended September 30, 2022.

November 3, 2022
·
8 min read
BioMidwest

Merck KGaA, Darmstadt, Germany and p-Chip Corporation Collaborate to Improve Trust and Transparency in Machine-to-Machine Driven Industrial Value Chains

Merck KGaA, Darmstadt, Germany announced the conclusion of a joint development agreement to develop and implement a new solution that offers never-before-seen levels of digital trust in machine-to-machine -connected industrial value chains.

November 3, 2022
·
3 min read
BioMidwest

Bio-Techne to Present at the Credit Suisse 31st Annual Healthcare Conference

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST.

November 3, 2022
·
2 min read
CollPlant to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 17

CollPlant Biotechnologies announced that Eran Rotem, Collplant’s Deputy CEO and Chief Financial Officer, will present a company overview at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum at the Westin NY Grand Central Hotel.

November 3, 2022
·
4 min read
Drug Development

Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022

Pathios Therapeutics Limited announced that new preclinical data highlighting the therapeutic potential of the company’s novel GPR65 inhibition platform will be the focus of a poster presentation at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer.

November 3, 2022
·
2 min read
Business

Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, reported financial results for the third quarter ended September 30, 2022 and provided a business update.

November 3, 2022
·
15 min read
Business

Akumin to Host Third Quarter 2022 Financial Results Call on November 10, 2022

Akumin Inc. will host a conference call at 8:30 a.m. Eastern Time , November 10, 2022 , to discuss its third quarter 2022 financial results.

November 3, 2022
·
3 min read
Business

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2022 and provided program updates.

November 3, 2022
·
11 min read